Atinary Technologies, whose no-code AI platform, SDLabs, and Self-Driving Labs technology are transforming research and development (R&D) of new molecules and chemicals, has announced a strategic collaboration with Snapdragon Chemistry, a Cambrex company and a leader in active pharmaceutical ingredient (API) process development.
 
Through this collaboration, Snapdragon has integrated its proprietary LabOS software platform with Atinary’s SDLabs platform to build a fully-automated and AI-driven, medium-throughput Solid-Phase Oligonucleotide Synthesizer (SPOS) for the purpose of autonomous multi-objective process optimizations. By using Atinary’s AI platform, Snapdragon’s process optimization campaign has demonstrated significant improvements across the tested applications, with up to an 18% increase in product yield and a 22% reduction in cost compared to processes previously optimized by an experienced scientist.
 
“Atinary is committed to accelerating innovation and delivering cutting-edge solutions to our customers,” said Dr. Hermann Tribukait, Co-Founder and CEO of Atinary Technologies. “Our work with Snapdragon showcases the power of our AI and data-driven process to solve complex chemistry and molecular discovery challenges in the pharmaceutical and biotech industry, orders of magnitude faster than traditional methods.”
 
Snapdragon’s laboratories and process development capabilities, along with its ability to design and build self-contained reactors, will be instrumental in this collaboration.
 
“We are excited about the opportunity to expand Snapdragon’s technological capability by integrating Atinary’s AI technology in our process R&D activities,” said Dr. Eric Fang, General Manager of Snapdragon Chemistry. “We believe that our combined expertise and shared vision for accelerated innovation will lead to significant advancements and added value for our customers, streamlining and expediting drug development pipelines and R&D portfolios.”